GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

OBIO · Jun 30, 2026

Orchestra BioMed Holdings, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001104659-26-093357General Corporate

Capex intensity100thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

288.64% · OPTIONAL · VALID

Operating cash generation0thOwn-history percentile · N=8

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-21968.18% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-89.47% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure100thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

284.09% · OPTIONAL · VALID

Gross margin13thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.gross_margin

71.59% · CORE · VALID

Operating margin0thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.operating_margin

-25404.55% · CORE · VALID

R&D intensity100thOwn-history percentile · N=8

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

18852.27% · OPTIONAL · VALID

SBC intensity100thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2846.59% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/9 normalizedLevel 3 Sep 30, 20250/9 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20260/9 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 167.27%
Current: 288.64%
Delta: 121.36%

Cash Generation Decreased

Previous: -20152.73%
Current: -21968.18%
Delta: -1815.45%

Growth Decreased

Previous: -87.33%
Current: -89.47%
Delta: -2.15%

Inventory Pressure Increased

Previous: 251.82%
Current: 284.09%
Delta: 32.27%

Margin Increased

Previous: 70.91%
Current: 71.59%
Delta: 0.68%

Profitability Decreased

Previous: -20069.09%
Current: -25404.55%
Delta: -5335.45%

R And D Intensity Increased

Previous: 14346.36%
Current: 18852.27%
Delta: 4505.91%

Sbc Intensity Increased

Previous: 2591.82%
Current: 2846.59%
Delta: 254.77%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Surgical & Medical Instruments & Apparatus peers →Has State · Orchestra BioMed Holdings, Inc. →Transitioned To · OBIO Fundamental State →Transitioned To · OBIO CAPEX_INTENSITY_INCREASED →Transitioned To · OBIO CASH_GENERATION_DECREASED →Transitioned To · OBIO GROWTH_DECREASED →Transitioned To · OBIO INVENTORY_PRESSURE_INCREASED →Transitioned To · OBIO MARGIN_INCREASED →Transitioned To · OBIO PROFITABILITY_DECREASED →Transitioned To · OBIO R_AND_D_INTENSITY_INCREASED →Transitioned To · OBIO SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.